Skip to main content
SpringerLink
Log in

Assessing anthracycline cardiotoxicity in the 1990s

  • Editorial
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alexander J, Dainiak N, Berger HJ, etal. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.N Engl J Med 1979; 300: 278–283.

    Google Scholar 

  2. Dardir MH, Ferrans VJ, Mikhael SY, etal. Cardiac morphologic and functional changes induced by epirubicin chemotherapy.J Clin Oncol 1989; 7: 947–958.

    Google Scholar 

  3. Druck MM, Gulenchyn KY, Evans WK, etal. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.Cancer 1984; 53: 1667–1674.

    Google Scholar 

  4. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycininduced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48: 4766–4769.

    Google Scholar 

  5. Lee BH, Goodenday LS, Muswick GJ, etal. Alterations in left ventricular diastolic function with doxorubicin therapy.J Ain Coll Cardiol 1987; 9: 184–188.

    Google Scholar 

  6. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: hemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Br Heart J 1986; 55: 274–282.

    Google Scholar 

  7. Severs NJ, Twist VW, Powell T. Acute effects of adriamycin on the macromolecular organization of the cardiac muscle cell plasma membrane.Cardioscience 1991; 2: 35–45.

    Google Scholar 

  8. Lipshultz SE, Colan SD, Gelber RD, etal. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood.N Engl J Med 1991; 324: 808–815.

    Google Scholar 

  9. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients.Med Pediatr Oncol 1995; 24: 352–361.

    Google Scholar 

  10. Strashun A. Adriamycin, congestive cardiomyopathy, and metaiodobenzylguanidine [editorial].J Nucl Med 1992; 33: 215–222.

    Google Scholar 

  11. Schwartz RG, McKenzie MB, Alexander J, etal. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy.Am J Med 1987; 82: 1109–1118.

    Google Scholar 

  12. Van Hoff DD, Layard MW, Basa P, etal.Risk factors for doxorubicin-induced congestive heart failure.Ann Intern Med 1979; 91: 710–717.

    Google Scholar 

  13. Speyer JL, Green MD, Kramer E, etal. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer.N Engl J Med 1988; 319: 745–752.

    Google Scholar 

  14. Legha SS, Benjamin RS, Mackay B, etal. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Ann Intern Med 1982; 96: 133–139.

    Google Scholar 

  15. Lokich J, Bothe A, Zipoli T, etal. Constant infusion schedule for adriamycin: a phase 1-II clinical trial of a 30 day schedule by ambulatory pump delivery system. J Clin Oncol 1983; 1: 24–28

    Google Scholar 

  16. Bacci G, Picci P, Ferrari S, etal. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.J Chemother 1993; 5: 237–246.

    Google Scholar 

  17. Ewer MS, Ali MK, Mackay B, etal. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin.J Clin Oncol 1984; 2: 112–117.

    Google Scholar 

  18. Lipshultz SE, Sanders SP, Goorin AM, etal. Monitoring for anthracycline cardiotoxicity.Pediatrics 1994; 93: 433–437.

    Google Scholar 

  19. Blatt J, DeLaat C, Fricker FJ, Janosky JE. Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.Pediatr Hematol Oncol 1995; 12: 61–66.

    Google Scholar 

  20. Mameghan H, Fischer RJ, O'Gorman-Hughes D, etal. Swing's sarcoma: long term follow up in 49 patients treated from 1967 to 1989.Int J Radiat Oncol Biol Phys 1993; 25: 431–438.

    Google Scholar 

  21. Nakada S, Ogawa S. Hirayama T. Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography.Nippon Ika Daigaku Zasshi 1994: 61: 209–219.

    Google Scholar 

  22. Aviles A, Arevila N, Diaz Maqueo JC, etal. Late cardiac toxicity of doxorubicin, epirubicin and mitoxantrone therapy for Hodgkin's disesae in adults.Leuk Lymphoma 1993; 11: 275–279.

    Google Scholar 

  23. GanzWI, Sridar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.Am J Clin Oncol 1993; 16: 109–112.

    Google Scholar 

  24. Palmeri ST, Bonow RO, Myers CE, etal. Prospective evaluation of doxorubicin by rest and exercise radionuclide angiography.Am J Cardiol 1986; 58: 607–613.

    Google Scholar 

  25. Steinherz LJ, Graham T, Hurwitz R, etal. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group.Pediatrics 1992; 89: 942–949.

    Google Scholar 

  26. Stoddard MF, Seeger J, Liddell NE, etal. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.J Am Coll Cardiol 1992; 20: 62–69.

    Google Scholar 

  27. Cittadini A, Fazio S, D'Ascia C, etal. Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study.Eur Heart J 1991; 12: 1000–1005.

    Google Scholar 

  28. Estorch M, Carrió I, Bernd L, etal. Indium- 111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.J Nucl Med 1990; 12: 1965–1970.

    Google Scholar 

  29. Carrió I, EstorchM, Berná L, etal. Assessment of anthracycline-induced myocardial damage by quantitative indium-111 myosin-specific monoclonal antibody studies.Eur J Nucl Med 1991; 18: 806–812.

    Google Scholar 

  30. Carrió I, Lopez-Pousa A, Estorch M, etal. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium111-antimyosin monoclonal antibody studies.J Nucl Med 1993; 34: 1503–1507.

    Google Scholar 

  31. Valdés-Olmos R, Ten Bokkel Huinink WW Ten Hoeve RF, etal. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracyclineassociated left ventricular dysfunction.Ann Oncol 1994; 5: 617–627.

    Google Scholar 

  32. Narula J, Strauss HW Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence.J Nucl Med 1993; 9: 1507–1509.

    Google Scholar 

  33. Praet M, Ruysschaert JM. In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives.Biochim Biophys Acta 1993; 1149: 79–85.

    Google Scholar 

  34. Wakasugi S, Wada A, Hasegawa Y, Naano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine- 125-metaiodobenzylguanidine.J Nucl Med 1992; 33: 208–214.

    Google Scholar 

  35. Wakasugi S, Fischman AJ, Babich JW etal. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.J Nucl Med 1993; 34: 1282–1286.

    Google Scholar 

  36. Valdés-Olmos S, ten Bokkel Huinink WW, Greve JC, etal. 1123 MIBG and serial radionuclide angiocardiography in doxo rubicin-related cardiotoxicity.Clin Nucl Med 1992; 17: 163–167.

    Google Scholar 

  37. Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, etal. Assessment of anthracycline-related myocardial adrenergic derangement by 1231-MIBG scintigraphy.Ear J Cancer 1995; 31A: 26–31.

    Google Scholar 

  38. Carrió I, Estorch M, Bernd L, etal.111In-antimyosin and123I-MIBG studies in the early assessment of doxorubicin cardiotoxicity.J Nucl Med 1995; 36: 2044–2049.

    Google Scholar 

  39. Miyagawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.Eur J Nucl Med 1991; 18: 332–338.

    Google Scholar 

  40. Piwnica-Worms D, Chin ML, Kronauge IF. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-sestamibi.Cancer Chemother Pharmacol 1993;32:385–391.

    Google Scholar 

  41. Takeishi Y, Sukekawa H, Sakurai T, etal. Noninvasive identification of anthracycline cardiotoxicity: comparison of 1231_ MIBG and123I-BMIPP imaging.Ann Nucl Med 1994; 8: 177–182.

    Google Scholar 

  42. Gianni L, Munzone E, Capri G, etal. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose and sequence-finding study.J Clin Oncol 1996, in press.

  43. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.Ann Intern Med 1987; 106: 814–816.

    Google Scholar 

  44. Gaudin PB, Hruban RH, Beschorner WE, etal. Myocarditis associated with doxorubicin cardiotoxicity.Am J Clin Pathol 1993; 100: 158–163.

    Google Scholar 

  45. Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff L. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection.Cancer 1994; 74: 182–188.

    Google Scholar 

  46. Pihkala J, Saarinen UM, Lundstrom U, etal. Effects of bone marrow transplantation on myocardial function in children.Bone Marrow Transplant 1994; 13: 149–155.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Nuclear Medicine and Medical Oncology, Hospital de Sant Pau, Barcelona, Spain

    Ignasi Carrió, Montserrat Estorch & Antonio López-Pousa

Authors
  1. Ignasi Carrió
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Montserrat Estorch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio López-Pousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carrió, I., Estorch, M. & López-Pousa, A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 23, 359–364 (1996). https://doi.org/10.1007/BF01247361

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01247361

Search

Navigation